CA
NZ
UK
AU
IND
US
Keros Therapeutics, Inc. (NASDAQ: KROS), a clinical‑stage biopharma company, is set to obtain a $20 million development milestone from Takeda Pharmaceuticals U.S.A. Inc. The payment reflects a key advancement in the development of elritercept, Keros’ lead product candidate, as the ELRiSE MDS Phase 3 …
The company also kept its quarterly dividend steady. Shares have shown price appreciation consistent with market trends, reflecting investor optimism about the upgraded forecasts.
Liminatus Pharma, Inc. has reported a significant development as it now believes its stockholders' equity is over $2.5 million, driven primarily by its ongoing merger with InnocsAI LLC. This financial enhancement marks a key shift for the company, especially as it navigates compliance verification …
Linde's Q2 2026 results show strong growth, with net income of $1.93 billion and an adjusted EPS of $4.50, strengthening future guidance.
LogicMark, Inc. (OTC: LGMK) has made a significant move in enhancing its capital structure by entering into a securities purchase agreement to sell 250,000 shares of its Series J Convertible Preferred Stock for a purchase price of $1.00 each. The transaction aims to provide …
Madrigal Pharmaceuticals has reported second-quarter 2026 net revenues of $364.3 million, reflecting a 71% increase year-over-year. Despite this significant growth, the company faces challenges with a net loss of $57.9 million, underscoring ongoing market pressures.Key HighlightsMadrigal Pharmaceuticals achieved net revenues of $364.3 million in …
Merit Medical Systems (NASDAQ: MMSI) posted earnings per share of $1.19 for the quarter ending June 30, beating the $0.98 consensus estimate. Over the past month the shares have risen 20.2%, despite a 3.6% decline year‑to‑date, and remain between the 52‑week lows of $59.74 …
Jasper Therapeutics, Inc. disclosed that a contingent $30.0 million payout will be distributed if the U.S. Food and Drug Administration grants a Priority Review Voucher for its experimental antibody briquilimab on or before Dec 31 2028. The milestone hinges on a regulatory decision, making …
This growth aligns with an EPS of $-0.42, matching analyst expectations. The significant revenue jump indicates strong demand across its oncology and screening product lines, showcasing the company’s resilience in the competitive oncology diagnostics market. The solid financial performance enhances investor confidence, especially as …
Henry Schein Inc. (NASDAQ: HSIC) is initiating leadership transitions that will see Chief Operating Officer Michael S. Ettinger and Chief Strategic Officer Mark E. Mlotek step down to senior advisory positions by October 30, 2026. Such restructuring may signal a recalibration of leadership roles …
Please wait processing your request...